PT  - JOURNAL ARTICLE
AU  - Tadashi Namisaki
AU  - Elke Schaeffeler
AU  - Hiroshi Fukui
AU  - Hitoshi Yoshiji
AU  - Yoshiyuki Nakajima
AU  - Peter Fritz
AU  - Matthias Schwab
AU  - Anne T. Nies
TI  - Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma
AID  - 10.1124/dmd.114.059832
DP  - 2014 Dec 01
TA  - Drug Metabolism and Disposition
PG  - 2033--2040
VI  - 42
IP  - 12
4099  - http://dmd.aspetjournals.org/content/42/12/2033.short
4100  - http://dmd.aspetjournals.org/content/42/12/2033.full
SO  - Drug Metab Dispos2014 Dec 01; 42
AB  - Targeted chemotherapy for hepatocellular carcinoma (HCC) is impaired by intrinsic and/or acquired drug resistance. Because drugs used in HCC therapy (e.g., anthracyclines or the tyrosine kinase inhibitor sorafenib) are substrates of uptake and/or efflux transporters, variable expression of these transporters at the plasma membrane of tumor cells may contribute to drug resistance and subsequent clinical response. In this study, the variability of expression of uptake transporters [organic cation transporter (OCT) 1 and OCT3] and efflux transporters [multidrug resistance 1 (MDR1)/P-glycoprotein, multidrug resistance protein (MRP) 1, MRP2, and breast cancer resistance protein (BCRP)], selected for their implication in transporting drugs used in HCC therapy, was investigated. HCC and corresponding nontumor tissue samples were collected from 24 Japanese patients at the time of surgery. Protein expression was determined by immunohistochemistry. Expression data were correlated with clinicopathological characteristics and patients’ outcome (median follow-up, 53 months). Generally, expression was highly variable among individual tumor samples. Yet median expression of OCT1, OCT3, and MDR1 in HCC was significantly lower (1.4-, 2.7-, and 2-fold, respectively) than in nontumor tissue, while expression of MRP2 persisted and BCRP showed a trend of increased levels in HCC. Patients with low BCRP expression had significantly shorter overall and recurrence-free survival times. Results suggest different expression patterns of drug transporters in HCC, which are associated only in part with clinicopathological characteristics. Detailed information on expression of drug transporters in HCC may be promising for individualization and optimization of drug therapy for liver cancer.